Home page A B C D E F G H I K L M N O P Q R S T U V W X Y Z

Sanofi otc products



Sanofi Unloads Five OTC Drugs to Ipsen for 88 Million to Pave Way

12.25.2017 | Nathan Becker

Sanofi (SNY) Unloads Five OTC Drugs to Ipsen (IPN.PA) for $88 Million to Pave Way for Boehringer Ingelheim Deal.

The portfolio also includes Buscopan2, an antispasmodic; Suppositoria Glycerini3, a laxative; and Mucothiol and Mucodyne4, expectorants for cough and flu. Combined, these regional brands span a geographic scope of eight European countries. Manufacturing will be provided by third parties. The most significant product is Prontalgine, an analgesic for the treatment of moderate to severe pain, which has grown at double digit rates over the last four years and is available only in France.

In 2015, R&D expenditures neared €193 million.

Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products

11.24.2017 | Logan Miers

Ipsen to pay €83 million cash upon closing for the products. agreement to acquire from Sanofi five consumer healthcare products in certain European territories. 1 OTx: Combination of prescription and over-the-counter.

Ipsen to pay €83 million cash upon closing for the products.

Ipsen is a global specialty-driven pharmaceutical group committed to discovering new solutions for targeted debilitating diseases and improving quality of life for patients.

Along with our dedication to improving the lives of patients, Ipsen is also firmly committed to protecting the environment and to supporting civil society and the communities in which we operate.

The corporate website of the Group is governed by the Code of Good Practices of the International Federation of Pharmaceutical Manufacturers Associations.

3 Sold in the Czech Republic.

4 Sold in Greece and the Republic of Ireland, respectively.

Combined, these regional brands span a geographic scope of eight European countries.

Sanofi to sell OTC products to Ipsen

3.16.2017 | Jennifer Bargeman

Sanofi is selling certain European rights to five consumer healthcare products to fellow French drugmaker Ipsen, in a move that will help.

Ipsen to buy cancer drugs from Merrimack.

£45000 per annum Car, Pension and a fantastic OTE.

Ispen said it is paying 83 million euros ($88 million) in cash for access to the consumer healthcare products in certain European territories, the most significant of which it considers to be Prontalgine, an analgesic for the treatment of moderate to severe pain,which has grown at double digit rates over the last four years and is available only in France.

From Sanofi's side, the move stems from the EC's requirement for it to divest certain assets in order to close a proposed consumer healthcare asset swap with Boehringer.

Competitive Salary and Package Competitive Salary Package Competitive Salary Package Competitive Salary Bonus.

Sanofi is selling certain European rights to five consumer healthcare products to fellow French drugmaker Ipsen, in a move that will help progress its planned asset swap deal with Boehringer Ingelheim.

Ipsen shells out up to $855m on Exelixis drug.

Ipsen's Jean Fabre, executive vice president of Primary Care, said the new assets will expand the firm's OTx portfolio and enhances its value proposition to consumers.

8-10 Dryden Street Covent Garden London WC2E 9NA.

Sanofi

8.21.2017 | Logan Blare

Moreover, increasing the number of over-the-counter (OTC) drugs will help governments ease the pressure on public healthcare, allowing consumers to treat.

Tools content (print, share, increase/decrease text size): Size.

And a healthy population begins with personal health. That’s why we’re committed to providing consumers around the world with self-care solutions that empower them to better manage their personal health. At Sanofi Consumer Healthcare, we believe the best advocate you can have for your own health and well-being is yourself. In an ever-changing world, only a healthy population will be able to rise to the societal and economic challenges of tomorrow.

The surveys reveal the following about over-the-counter medicines:

Healthcare Solutions You are here:

Empowering individuals to manage their own health will become increasingly important in the years to come.

Sanofi Agrees to Sell Five Over-the-Counter Drugs to Ipsen

5.18.2017 | Jennifer Bargeman

Sanofi agreed to sell some over-the-counter products to Ipsen SA as it edges closer to completing a 22.8 billion-euro ($24.2 billion) asset swap.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accuray delivers business and financial information, news and insight around the world.

Ipsen said it expects to complete the purchase in the second quarter. French drugmaker Ipsen emerged as the preferred bidder after a competitive sale process involving other pharmaceutical companies, the person said.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accuray delivers business and financial information, news and insight around the world.

EMEA +44 20 7330 7500.

EMEA +44 20 7330 7500.

Americas +1 212 318 2000.

Asia Pacific +65 6212 1000.

Ipsen will pay 83 million euros for five products including Prontalgine, a painkiller, the Paris-based company said in a statement Monday. Bloomberg previously reported the deal was close, citing a person familiar with the situation.

Sanofi agreed to sell some over-the-counter products to Ipsen SA as it edges closer to completing a 22.8 billion-euro ($24.2 billion) asset swap with Boehringer Ingelheim GmbH.

Asia Pacific +65 6212 1000.

Americas +1 212 318 2000.

The assets were mostly treatments that can be bought without the prescription of a doctor, known as OTC products.